Agents Targeted Against PSMA for Prostate Cancer
In this interview with Targeted Oncology, Scott T. Tagawa, M.D., The Richard A. Stratton Associate Professor in Hematology and Oncology and associate professor of Clinical Medicine and Urology, discusses PSMA-targeting agents for the treatment of prostate cancer.
- As resistance to AR-targeted therapy develops, PSMA expression will increase in many patients. An agent targeted against PSMA could be added in at this time.
- PSMA-targeted therapy could also potentially be used in combination with AR-targeted therapy.
- Both AR- and PSMA-targeted therapies are being investigated in clinical trials and are already making an impact.